Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751386 · ClinicalTrials.gov registry record · Phase 2
Baclofen for Treating Anxiety and Alcoholism
A Phase 2 study of Alcohol Drinking and Alcoholism, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01751386 is a Phase 2 study of Alcohol Drinking and Alcoholism that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 39 participants, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01751386, a Phase 2 study of Alcohol Drinking and Alcoholism, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Baclofen is a drug used to control muscle stiffness in people with neurological diseases. Some studies suggest that baclofen may reduce alcohol craving and use. It helps to reduce anxiety in alcoholics, which in turn can help to reduce cravings. Researchers want to see if baclofen can be a safe and effective treatment for alcoholics who have high anxiety levels. Objectives: \- To see if baclofen is safe and helpful for people who have alcoholism and high anxiety levels. Eligibility: * Individuals between 21 and 65 years of age who have been diagnosed with alcoholism and anxiety issues. * Participants must not be taking anti-anxiety medication. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tests of alcohol dependency and anxiety levels will also be given. * Participants will be divided into two groups. One group will take baclofen. The other group will have a placebo. * About 1 week after the screening visit, participants will have a study visit. They will answer questions about their behavior and mood. They will then start to take either baclofen or a placebo. Participants will take the study drug three times a day, every day. * After 1 week on the study drug, participants will have an overnight stay at the National Institutes of Health. They will have blood tests and answer questions about mood and behavior. They will also have tests that involve choosing to drink alcohol and answering more questions about cravings. * Participants will stop taking their study drug over a 3-day period. * A final follow-up visit will be required 1 week after the overnight study visit. Participants will receive information about other alcohol abuse treatment programs.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Baclofen
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-12-03 |
| Est. Completion | 2016-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01751386
The ClinicalTrials.gov registry entry for NCT01751386 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (94% lower). The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Alcohol Drinking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01751386 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01751386 about?
NCT01751386 is a clinical study titled "Baclofen for Treating Anxiety and Alcoholism". Background: \- Baclofen is a drug used to control muscle stiffness in people with neurological diseases. Some studies suggest that baclofen may reduce alcohol craving and use. It helps to reduce anxiety in alcoholics, which in turn can help to reduce cravings. Researchers want to see if baclofen ca...
What is the current status of trial NCT01751386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2012-12-03. Estimated completion is 2016-08-17.
What conditions does trial NCT01751386 study?
This clinical trial studies the following conditions: Alcohol Drinking, Alcoholism, Alcohol Dependence, Anxiety Disorder, Alcohol Drinking Related Problems.
What interventions are being tested in trial NCT01751386?
The interventions under investigation include: Placebo (OTHER), Baclofen (DRUG).
Who is sponsoring clinical trial NCT01751386?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01751386 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Drinking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
Ketone Ester Intervention in Alcohol Use Disorder
RECRUITING · Phase 2
-
Effects Ketone Supplement and Alcohol on Brain Metabolism
RECRUITING · Phase 2
-
Effect of Nutritional Ketosis on Alcohol Metabolism
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Acute Effects of Ketone Supplement on Responses to Alcohol Challenge in Healthy Volunteers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.